Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 191

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 191
---

  
    Accrued professional fees 
     72,054  
     39,165 
  
    Accrued research and development 
     860,958  
     439,024 
  
    Accrued board fees 
     117,750  
     117,750 
  
    Delaware franchise taxes payable 
     -  
     40,000 
  
    Other accrued expenses 
     17,228  
     17,330 
  
    Total accounts payable and other current liabilities 
    $3,309,717  
    $2,672,327 

NOTE
5: STOCK-BASED COMPENSATION

The
Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the “2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company’s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.

    F-11

A
summary of the stock option activity during the year ended December 31, 2024, is presented in the table below:

 SCHEDULE
OF STOCK OPTION ACTIVITY 

    Weighted average  

    Number of  options  
    Exercise  price  
    Remaining  contractual  life  (in years)  
    Intrinsic value 
  
    Outstanding as of January 1, 2024 
     2,050,197  
    $10.90  
     7.9  
    $36,363 
  
    Granted 
     838,250  
    $1.54  
     -  
    $- 
  
    Forfeited and cancelled 
     (625) 
    $-  
     -  
    $- 
  
    Outstanding as of December 31, 2024 
     2,887,822  
    $8.06  
     7.6  
    $- 
  
    Exercisable as of December 31, 2024 
     1,854,